Stay updated on Sovaldi Plus Rebetol in Genotype 2 HCV Clinical Trial
Sign up to get notified when there's something new on the Sovaldi Plus Rebetol in Genotype 2 HCV Clinical Trial page.

Latest updates to the Sovaldi Plus Rebetol in Genotype 2 HCV Clinical Trial page
- Check5 days agoChange DetectedThe record describes a completed post-marketing surveillance study of Sovaldi plus Rebetol in Japanese adults with genotype 2 hepatitis C, evaluating real-world safety and efficacy. It reports 554 participants and includes study design, outcomes, and 45 locations.SummaryDifference46%

- Check12 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAn NIH-wide notice about updated terminology during the agency’s website transition appears above the page, and the displayed site revision changes from v3.7.1 to v3.7.2. The study record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check40 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check47 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the usual study record content and navigation, indicating access to this resource is blocked.SummaryDifference0.5%

- Check54 days agoChange DetectedA large collection of MeSH terms, disease keywords, drug names, sponsor/investigator details, and location data was removed from the study record. This removal reduces the contextual and discoverability information associated with the post-marketing hepatitis C study in Japan.SummaryDifference14%

Stay in the know with updates to Sovaldi Plus Rebetol in Genotype 2 HCV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sovaldi Plus Rebetol in Genotype 2 HCV Clinical Trial page.